Leading Cancer Visualization
As minimally invasive and robotic-assisted surgery have become the standard of care for many cancer surgeries, Vergent is focused on helping surgeons realize the full potential of these procedures by significantly improving the visibility of tumors.
The company is developing tumor-targeted agents that enhance surgeons’ ability to visualize tumors, which may make cancer surgery more successful for them and their patients.
Vergent’s lead program, VGT-309, is a targeted fluorescent-imaging agent. The company is currently sponsoring a Phase 2b multi-center study evaluating VGT-309 in surgery for cancer in the lung at leading hospitals in the U.S. and Australia.